Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR II: Sintilimab + SCRT/Chemo for Rectal Cancer
NCT05484024Phase 3Not yet recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2022
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in rectal adenocarcinoma, sponsored by Chinese Academy of Medical Sciences. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05484024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484024.